| Literature DB >> 35123805 |
Hiroyo Yoshino1, Yuanzhe Li2, Kenya Nishioka3, Kensuke Daida2, Arisa Hayashida2, Yuta Ishiguro2, Daisuke Yamada2, Nana Izawa4, Katsunori Nishi2, Noriko Nishikawa2, Genko Oyama2, Taku Hatano2, Shinichiro Nakamura5, Asako Yoritaka6, Yumiko Motoi2, Manabu Funayama7, Nobutaka Hattori8.
Abstract
To investigate the prevalence and genotype-phenotype correlations of parkin RBR E3 ubiquitin protein ligase (PRKN) variants in Parkinson's disease (PD), we first included 2,527 patients with PD. Through the defined selection, we enrolled 2,322 patients, including 1,204 with familial and 1,118 with sporadic PD. We identified 242 patients harboring PRKN variants, which were thought to be susceptibility factors, comprising 137 patients with familial and 105 with sporadic PD; among the 26 identified variants, 13 were novel. We divided our cohort into 2 groups: heterozygote (hereafter called one-allele) and homozygote or compound heterozygote (hereafter called two-allele). The patients with two-allele were significantly younger at onset than those with one-allele. Six families harbored the complex forms of one- and two-allele in different individuals of the same family. The presence of two-allele reflected more frequent normal values of [123I] metaiodobenzylguanidine myocardial scintigraphy. The log-rank test revealed an exacerbation associated with two-allele over 15 years of the disease course. The patients with PRKN variants showed specific symptoms dependent on the number of mutated alleles.Entities:
Keywords: PARK2; PRKN; Parkinson's disease; genetics
Mesh:
Substances:
Year: 2022 PMID: 35123805 DOI: 10.1016/j.neurobiolaging.2021.12.014
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673